Grifols SA (GRF.MC) stock: key figures, P/E, revenue and dividend
Health Care · Spain · ISIN ES0171996087
Grifols SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 7.21 bn EUR | 7.52 bn EUR |
| Gross profit | 2.85 bn EUR | 2.69 bn EUR |
| Operating income | 1.32 bn EUR | 1.40 bn EUR |
| EBIT | 1.15 bn EUR | 1.22 bn EUR |
| Net income | 156.00 m EUR | 401.00 m EUR |
| Diluted EPS – continuing operations | 0.23 EUR | 0.58 EUR |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Grifols SA
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
More stocks
- Accelleron Industries AG (ACLN.SW)
- Avolta AG (AVOL.SW)
- Kinden Corp (1944.T)
- NIO Inc (NIO)
- B2Gold Corp (BTO.TO)
- Tongwei Co Ltd (600438.SS)
- FIRST INDUSTRIAL REALTY TRUST INC (FR)
- Shannon Semiconductor Technology Co Ltd (300475.SZ)
- Morningstar, Inc. (MORN)
- Guangzhou Automobile Group Co Ltd Class A (601238.SS)
- Choice Properties Real Estate Investment Trust (CHP.UN.TO)
- Kuang Chi Technologies Co Ltd (002625.SZ)
Not investment advice. All data without warranty, price as of 16.10.2026. Details in the risk notice.